Physician profile
Mark A Lijewski
NPI 1487625471
$2,122.31
in general payments reported to CMS, 2019-2025
25 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $116 · 2022: $252 · 2023: $485 · 2024: $537 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.47 | 2019-2025 | |
| Genzyme Corporation | $188.15 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.47 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.86 | 2019-2024 | Trulance |
| Janssen Biotech, INC. | $128.93 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $120.41 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $119.89 | 2023-2024 | Voquezna |
| Ucb, INC. | $80.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $46.16 | 2022-2024 | Injectafer |
| Qol Medical, LLC | $38.57 | 2025 | Sucraid |
| Redhill Biopharma INC. | $33.13 | 2020-2023 | Talicia |
| Merck Sharp & Dohme LLC | $29.57 | 2019-2020 | |
| Shionogi INC | $26.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.06 | 2025 | Iqirvo |
| Organon LLC | $25.39 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.26 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $20.67 | 2023 | Sutab |
| Sandoz INC. | $19.76 | 2022 | |
| Ardelyx, INC. | $17.81 | 2022 | |
| Celgene Corporation | $17.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.67 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.19 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $13.20 | 2023 | Ocaliva |
| Romark Laboratories, Lc | $12.88 | 2019 | |
| Allergan, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lijewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.